Klaus Schmierer
Klaus Schmierer
The Blizard Institute, Queen Mary University of London, Medicine & Dentistry//Barts Health NHS Trust
Verified email at - Homepage
Cited by
Cited by
Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain
K Schmierer, F Scaravilli, DR Altmann, GJ Barker, DH Miller
Annals of neurology 56 (3), 407-415, 2004
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
L Kappos, R Gold, DH Miller, DG MacManus, E Havrdova, V Limmroth, ...
The Lancet 372 (9648), 1463-1472, 2008
Association between pathological and MRI findings in multiple sclerosis
M Filippi, W Brück, D Chard, F Fazekas, JJG Geurts, C Enzinger, ...
The Lancet Neurology 18 (2), 198-210, 2019
Diffusion tensor imaging of post mortem multiple sclerosis brain
K Schmierer, CAM Wheeler-Kingshott, PA Boulby, F Scaravilli, ...
Neuroimage 35 (2), 467-477, 2007
No cerebrocervical venous congestion in patients with multiple sclerosis
F Doepp, F Paul, JM Valdueza, K Schmierer, SJ Schreiber
Annals of neurology 68 (2), 173-183, 2010
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
G Giovannoni, B Turner, S Gnanapavan, C Offiah, K Schmierer, M Marta
Multiple sclerosis and related disorders 4 (4), 329-333, 2015
High field MRI correlates of myelin content and axonal density in multiple sclerosis: a post-mortem study of the spinal cord
JP Mottershead, K Schmierer, M Clemence, JS Thornton, F Scaravilli, ...
Journal of neurology 250, 1293-1301, 2003
Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation
K Schmierer, CAM Wheeler‐Kingshott, DJ Tozer, PA Boulby, HG Parkes, ...
Magnetic Resonance in Medicine: An Official Journal of the International …, 2008
Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain
K Schmierer, DJ Tozer, F Scaravilli, DR Altmann, GJ Barker, PS Tofts, ...
Journal of Magnetic Resonance Imaging: An Official Journal of the …, 2007
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI
RA Farrell, D Antony, GR Wall, DA Clark, L Fisniku, J Swanton, Z Khaleeli, ...
Neurology 73 (1), 32-38, 2009
A review of structural magnetic resonance neuroimaging
M Symms, HR Jäger, K Schmierer, TA Yousry
Journal of Neurology, Neurosurgery & Psychiatry 75 (9), 1235-1244, 2004
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis
N Scolding, D Barnes, S Cader, J Chataway, A Chaudhuri, A Coles, ...
Practical neurology 15 (4), 273-279, 2015
Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis
D Baker, M Marta, G Pryce, G Giovannoni, K Schmierer
EBioMedicine 16, 41-50, 2017
Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab
D Baker, SS Herrod, C Alvarez-Gonzalez, G Giovannoni, K Schmierer
JAMA neurology 74 (8), 961-969, 2017
Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial
R Raftopoulos, SJ Hickman, A Toosy, B Sharrack, S Mallik, D Paling, ...
The Lancet Neurology 15 (3), 259-269, 2016
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
D Baker, CAK Roberts, G Pryce, AS Kang, M Marta, S Reyes, K Schmierer, ...
Clinical & Experimental Immunology 202 (2), 149-161, 2020
High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis
K Schmierer, HG Parkes, PW So, SF An, S Brandner, RJ Ordidge, ...
Brain 133 (3), 858-867, 2010
Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis
C Dobson-Stone, A Danek, L Rampoldi, RJ Hardie, RM Chalmers, ...
European Journal of Human Genetics 10 (11), 773-781, 2002
GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study
AD Goodman, H Rossman, A Bar-Or, A Miller, DH Miller, K Schmierer, ...
Neurology 72 (9), 806-812, 2009
Both cladribine and alemtuzumab may effect MS via B-cell depletion
D Baker, SS Herrod, C Alvarez-Gonzalez, L Zalewski, C Albor, ...
Neurology-Neuroimmunology Neuroinflammation 4 (4), 2017
The system can't perform the operation now. Try again later.
Articles 1–20